Affymetrix (NASDAQ: AFFX) will highlight its new Concurrent Molecular Analysis Profiling (CoMAP™) capability at the 2015 annual meeting of the American Association for Cancer Research. The program enables cancer researchers to gain rapid insight into the functional impact of DNA copy-number alterations by combining whole-genome copy-number data with gene expression profiles to easily and cost-effectively visualize and identify cancer driver events.
Recent whole-genome DNA analysis of cancer samples has demonstrated that copy-number alterations affect more of the genome than any other DNA abnormality. Many of these alterations are “drivers” of cancer, while others are merely “passenger” events. Deciphering which DNA alterations are “driver” versus “passenger” events has been a challenge. The new Affymetrix CoMAP capability enables the concurrent correlation of genome-wide gene expression changes with copy-number alterations, helping to rapidly identify and prioritize the number of potential driver events, which in turn can lead to the identification of functional biomarkers. ...
